Pharmaceuticals News and Research

RSS

Link between eosinophils and asthma

Mayo Clinic researchers have used a comparative genomic strategy to demonstrate a causative link between eosinophils, a rare type of white blood cell, and asthma.

18 Sep 2004

Wyeth supports FDA recommendation to strengthen antidepressant labeling

Statement by Wyeth Pharmaceuticals supporting the U.S. Food and Drug Administration (FDA) Joint Advisory Committee’s recommendation to strengthen the product labels across the antidepressant category regarding use in the pediatric population.

16 Sep 2004

One-third to buy cheaper Canadian drugs, 100 million find insurance coverage cut or costlier

Faced with a double-barreled crisis of shrinking health care coverage and fast-rising medical costs, two out of three American adults (67 percent) now think health care coverage should be a “guarantee” as in Canada, Britain and other nations.

16 Sep 2004

ChemGenex discovers five new depression genes

ChemGenex Pharmaceuticals has announced that it has filed for patent protection for a further five novel depression-associated gene targets discovered by its depression and anxiety research group.

16 Sep 2004

RNAi enlisted in hunt for prawn vaccines

CSIRO researchers are using a biological phenomenon called RNA interference (RNAi) in an effort to develop a major biotechnological breakthrough for the aquaculture industry - vaccines for common prawn diseases.

16 Sep 2004

Labor says it would fund the public education anti-smoking campaign, if elected

Australian Medical Association (AMA) President, Dr Bill Glasson, said today that Labor’s promise to inject another $21 million into anti-smoking awareness campaigns would send a strong message to the community to quit the killer habit.

16 Sep 2004

Celacade shown to reduce risk of death and hospitalization in patients with advanced chronic heart failure

Vasogen has announced that comprehensive results from the Company's phase II trial of Celacade (immune modulation therapy) in advanced chronic heart failure patients were published in the September 15 issue of the Journal of the American College of Cardiology (JACC).

16 Sep 2004

Stem cell science and orthopedic surgery may reduce failure rate in hip replacements

By combining stem cell science with orthopedic surgery, a team of researchers at the University of British Columbia and Vancouver Coastal Health Research Institute aims to reduce the 10 per cent failure rate in hip replacements and make repeat replacements and other joint repairs obsolete within 10-15 years.

16 Sep 2004

Which provincial pharmacare system works best to protect Canadians against catastrophic drug costs?

Health-care economy researchers at the University of British Columbia have found there is wide variation in coverage for pharmaceuticals in Canada.

14 Sep 2004

Wyeth gets approval for needle-less syringe for the treatment of hemophilia

Wyeth Pharmaceuticals has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the ReFacto Antihemophilic Factor (Recombinant) R2 Kit, the first needle-less reconstitution device with a prefilled diluent syringe for hemophilia.

14 Sep 2004

Micro-thin implantable films may one day allow patients to forgo daily injections and pills

Researchers at the Georgia Institute of Technology have developed a material that may one day allow patients to forgo daily injections and pills and receive prescriptions instead through micro-thin implantable films that release medication according to changes in temperature.

14 Sep 2004

Researchers find way to clean up the drugs market

Researchers from the University of Cambridge and the Massachusetts Institute of Technology have made a breakthrough by using supercritical carbon dioxide (scCO2) as a reaction medium for the preparation of molecules of interest to the pharmaceutical industry.

13 Sep 2004

Schering-Plough and Bayer form strategic alliance

Schering-Plough Corporation has announced that it has entered into a strategic agreement with Bayer designed to maximize the companies' pharmaceutical resources while maintaining each company's own strategic interests.

13 Sep 2004

Yentreve available in Europe for treatment of stress urinary incontinence

Yentreve (duloxetine hydrochloride) is now available in certain European countries, giving women suffering from moderate to severe stress urinary incontinence (SUI) a pharmaceutical treatment option for the first time.

13 Sep 2004

Chiropractic correction may help reverse multiple sclerosis and Parkinson’s disease

A recent study of 81 cases, published in the Journal of Vertebral Subluxation Research (JVSR), is the first to show that correction of upper neck injuries may reverse the progression of both Multiple Sclerosis (MS) and Parkinson’s disease (PD).

10 Sep 2004

DEA approves retail alert network

The U.S. Drug Enforcement Administration (DEA) has announced its partnership with the National Association of Chain Drug Stores (NACDS) for the implementation of the Retail Alert Network (RAN), an online information hub and analysis resource for crimes occurring in and around retail outlets and local communities.

10 Sep 2004

Painful and damaging chemotherapy may one day be a thing of the past

Researchers at the Georgia Institute of Technology and Purdue University have developed nano-sized particles that can target and trick cancer cells into absorbing them.

10 Sep 2004

Chemical pathways of serotonin in the nervous system pave way for future pharmaceutical treatments for depression

From mollusks to mammals, newly discovered chemical pathways of serotonin in the nervous system are paving a path toward future pharmaceutical treatments for depression and other disorders.

10 Sep 2004

Researchers keep milk free of contaminants

Dairy farms in the United States produced more than 170 billion pounds of milk last year. The more than 9 million cows that produced that milk occasionally need to be treated for various ailments

8 Sep 2004

Phase I clinical trial of new drug for severe asthma

Cambridge Antibody Technology today announced that it is starting a Phase I clinical trial of CAT-354, a human anti-IL-13 monoclonal antibody, which is a potential treatment for severe asthma, following recent approval from the Medicines and Healthcare products Regulatory Agency (MHRA).

8 Sep 2004